Nov 24 (Reuters) - Trimel Pharmaceuticals Corp TRL.TO :
* Announces exclusive license agreement with endo for Natesto
* Trimel will be responsible for the manufacture of Natesto and receive a tiered supply price for the product
* Is eligible to receive payments of up to us$165 million based on certain regulatory and sales milestones
* eligible to receive upfront fee of $25 mln and prepaid inventory deposit of $5 million upon closing of the deal
* Unit trimel biopharma srl, signed agreement providing affiliate of Endo International exclusive rights to market natesto in U.S., Mexico
* Source text for Eikon ID:nCCN1wKjMq
* Further company coverage TRL.TO
((Bangalore Newsroom; +1 646 223 8780))